2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - 243-245
Technology and Procedures, Assays, Imaging, Treatment Considerations, Non-Biological Therapies, Chemotherapy, Biological Processes, CHIP, Genomics, Immune Mechanism, Multi-Systemic Interactions, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric
PAPER

177 G-CSF receptor blockade inhibits NET formation by HbSS mouse neutrophils and suppresses neutrophil activation in human sickle cell disease

Gregory J. Kato, MD, Paolo Rossato, MD2, Julia Nguyen, BS3, Arne Wehling, PhD4, Fuad R. Abdulla, DVM5, Conglin Ruan, BS6, Chunsheng R. Chen, PhD7, Joan Denise Beckman, Lois, RichardKingAssistantProfessorandMcKnightLand-GrantProfessor8, Steffi Knoll Machado, PhD9, Timo Kraushaar, PhD10, Markus Brechmann, PhD11, Prithu Sundd, Ph.D12, Gregory M. Vercellotti I, MD13, John D. Belcher I, PhD14
1 CSL Behring, King of Prussia, Pennsylvania, United States
2 CSL Behring AG, Bern, Switzerland
3 University of Minnesota, Minneapolis, Minnesota, United States
4 CSL Behring AG, Bern, Switzerland
5 University of Minnesota, Minneapolis, Minnesota, United States
6 University of Minnesota, Minneapolis, Minnesota, United States
7 University of Minnesota, Minneapolis, Minnesota, United States
8 University of Minnesota, Minneapolis, Minnesota, United States
9 CSL Innovation GmbH, Marburg, Germany
10 CSL Innovation GmbH, Marburg, Germany
11 CSL Innovation GmbH, Marburg, Germany
12 Versiti Blood Research Institute & Blood Center of Wisconsin, Milwaukee, Wisconsin, United States
13 University of Minnesota, Minneapolis, Minnesota, United States
14 University of Minnesota, Minneapolis, Minnesota, United States

Introduction

Neutrophil extracellular traps (NETs) contribute to thrombo-inflammation, vaso-occlusion, and organ injury in sickle cell disease (SCD). Granulocyte colony-stimulating factor (G-CSF) administration can precipitate severe vaso-occlusive crisis (VOC) in patients with SCD and has been linked to neutrophil activation and NET formation (NETosis). Although NETs are increasingly recognized as mediators of VOCs, upstream regulators of NETosis in SCD remain incompletely characterized. We investigated whether G-CSF directly induces NET formation, and whether blockade of the G-CSF receptor (G-CSFR) suppresses NET formation by neutrophils from HbSS mice. We also explored the effects of G-CSFR inhibition on neutrophil activation in ex vivo samples from patients with steady-state SCD and healthy donors, and human SCD transcriptomic analyses were used to evaluate activation of G-CSF-dependent pathways during VOC. 

Methods

Four transcriptomic datasets from previous studies were analyzed; one dataset of healthy participants treated with G-CSF and three datasets of patients with SCD at baseline (steady-state) and in VOC. Bone marrow neutrophils were isolated from HbSS mice and stimulated with murine G-CSF (or unstimulated control) in the presence of the anti-mouse G-CSFR monoclonal antibody VR81 (or isotype control). In the ex vivo mouse samples, NET formation was quantified by fluorescence imaging of extracellular DNA (Sytox Orange), myeloperoxidase (MPO), and citrullinated histone H3 (CitH3). Whole blood samples obtained from healthy donors and patients with steady-state SCD were treated with fully human anti-G-CSFR monoclonal antibody (CSL324), stimulated with recombinant human G-CSF or TNFα, and analyzed by flow cytometry for expression of neutrophil activation markers (CD177 and Mac-1). 

Results

We derived a G-CSF signature from healthy participants treated with G-CSF. Across three transcriptomic datasets from patients with SCD, the G-CSF signature was significantly enriched during VOC compared with baseline, supporting activation of the G-CSF pathway during acute VOC events. The G-CSF signature and VOC signature (the set of genes upregulated in VOC versus baseline in all three datasets) strongly overlapped. Additional analysis demonstrated that G-CSF regulates the most characteristic (salient) VOC genes via the JAK/STAT pathway. These regulated VOC genes include the known NET-associated genes CD177, MMP8, OLFM4, ELANE, S100A12, and MPO. Ex vivo stimulation of HbSS mouse neutrophils with G-CSF induced NET formation, demonstrated by increased extracellular DNA, MPO, and CitH3 staining relative to unstimulated controls. Pretreatment of the HbSS mouse neutrophils with VR81 inhibited G-CSF-induced NET formation, compared with isotype control, establishing a direct mechanistic link between G-CSF signaling and NETosis. In whole blood samples from patients with SCD and healthy donors, G-CSF induced upregulation of the neutrophil activation markers CD177 and Mac-1, whereas CSL324 prevented G-CSF-mediated activation. These findings demonstrate pharmacologic inhibition of G-CSFR signaling in human neutrophils and support translation of the murine observations to human disease. 

Conclusions

G-CSF directly induces NETosis by neutrophils isolated from HbSS mice, and G-CSFR blockade suppresses both NET formation and neutrophil activation in mouse and human samples, respectively. These findings align with our previous in vivo studies in murine SCD models, which demonstrated that G-CSFR blockade reduced NET generation within liver microvasculature, decreased circulating NET embolization to the lung, and attenuated vaso-occlusion. Together with transcriptomic evidence demonstrating activation of G-CSF-responsive pathways during VOC, these findings identify the G-CSF/G-CSFR axis as an upstream regulator of NET-driven inflammation in SCD. The results provide mechanistic support for therapeutic targeting of G-CSFR and establish a translational link between inhibition of NETosis and suppression of neutrophil activation in SCD. These findings support the ongoing Phase 2 evaluation of CSL324 for the prevention of vaso-occlusive complications in patients with SCD (NCT07224360).

Gregory J. Kato, MD: CSL - Current equity holder in private company; CSL - Current Employment